‘Alder’ or nothing: biopharma files for $115M IPO
The bulls marched on as Alder Biopharmaceuticals Inc. joined the growing queue of biotechs seeking to prevail on the public markets. The Bothell, Wash.-based company filed a registration statement with the SEC seeking to raise up to $115 million in its initial public offering (IPO) to fund its ongoing clinical program for lead compound ALD403, a monoclonal antibody targeting calcitonin gene-related peptide, or CGRP, to prevent migraine headache. Filing as an emerging growth company, Alder plans to list on the Nasdaq Global Market under the ticker ALDR.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter